Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Peking University People's Hospital, Peking University Hepatology Institute, Beijing International Cooperation Base for Science and Technology On NAFLD Diagnosis, No.11 Xizhimen South Street, Beijing, 100044, China.
Henan Provincial People's Hospital, No.7 Weiwu Street, Zhengzhou, 463599, China.
BMC Infect Dis. 2024 Jan 10;24(1):72. doi: 10.1186/s12879-023-08940-3.
To investigate the trends in health-related quality of life (HRQoL) among hepatitis C virus (HCV) patients and to assess the longitudinal impact of antiviral therapy on their well-being.
In this prospective multicenter observational study in adults with HCV infection, sociodemographic, clinical characteristics and EQ-5D questionnaires were collected. Generalized estimating equation (GEE) models were used to assess the associations between these variables and changes in HRQoL over time.
456 patients were included, with a median age of 46.5 (36.5-57.0) years, of which 262 (57.5%) were males and 44 (9.6%) had cirrhosis. 335 patients (73.5%) receiving antiviral therapy and 61.8% achieved sustained virologic response (SVR). The baseline EQ-5D utility and EQ-VAS were 0.916 ± 0.208 and 80.6 ± 13.0. In multivariable analysis of GEE estimation, achieving SVR24 was positively associated with EQ-5D utility (p = 0.000) and EQ-VAS (p = 0.000) over time. Age and income were shown to be significant predictors of EQ-5D utility, while gender, age and genotype were associated with EQ-VAS over time.
SVR improved long-term HRQoL in HCV patients in the first few years following viral clearance. Certain sociodemographic factors, such as gender, age, income as well as genotype, significantly influenced long-term changes in patients' quality of life.
NCT01594554. Registration date: 09/05/2012.
本研究旨在探讨丙型肝炎病毒（HCV）患者健康相关生活质量（HRQoL）的变化趋势，并评估抗病毒治疗对其健康状况的纵向影响。
本前瞻性多中心观察性研究纳入了成年 HCV 感染者，收集了社会人口学、临床特征和 EQ-5D 问卷数据。采用广义估计方程（GEE）模型评估这些变量与 HRQoL 随时间变化的相关性。
共纳入 456 例患者，中位年龄为 46.5（36.5-57.0）岁，其中 262 例（57.5%）为男性，44 例（9.6%）患有肝硬化。335 例（73.5%）患者接受抗病毒治疗，61.8%获得持续病毒学应答（SVR）。基线 EQ-5D 效用和 EQ-VAS 分别为 0.916±0.208 和 80.6±13.0。GEE 估计的多变量分析显示，SVR24 与 EQ-5D 效用（p=0.000）和 EQ-VAS（p=0.000）随时间的改善呈正相关。年龄和收入是 EQ-5D 效用的显著预测因素，而性别、年龄和基因型与 EQ-VAS 随时间的变化相关。
清除病毒后最初几年，SVR 可改善 HCV 患者的长期 HRQoL。某些社会人口学因素，如性别、年龄、收入以及基因型，显著影响患者长期生活质量的变化。
NCT01594554。注册日期：2012 年 9 月 5 日。
